These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9046349)

  • 1. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
    Orjales A; Mosquera R; Labeaga L; Rodes R
    J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
    Heidempergher F; Pillan A; Pinciroli V; Vaghi F; Arrigoni C; Bolis G; Caccia C; Dho L; McArthur R; Varasi M
    J Med Chem; 1997 Oct; 40(21):3369-80. PubMed ID: 9341912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands.
    López-Rodríguez ML; Benhamú B; Morcillo MJ; Tejada I; Avila D; Marco I; Schiapparelli L; Frechilla D; Del Río J
    Bioorg Med Chem; 2004 Oct; 12(19):5181-91. PubMed ID: 15351401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM; Thompson DC; Bloomquist WE; Susemichel AD; Calligaro DO; Cohen ML
    J Med Chem; 1998 May; 41(11):1943-55. PubMed ID: 9599243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
    Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
    Chloń G; Pawłowski M; Duszyńska B; Szaro A; Tatarczńska E; Kłodzińska AL; Chojnacka-Wójcik E
    Pol J Pharmacol; 2001; 53(4):359-68. PubMed ID: 11990082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
    J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH; Milhahn H; Eich E
    J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists.
    Lasheras B; Berjón A; Montañés R; Roca J; Romero G; Ramírez MJ; Del Río J
    Arzneimittelforschung; 1996 Apr; 46(4):401-6. PubMed ID: 8740088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis by microwave irradiation and binding properties of novel 5-HT(1A) receptor ligands.
    Caliendo G; Fiorino F; Perissutti E; Severino B; Gessi S; Cattabriga E; Borea PA; Santagada V
    Eur J Med Chem; 2001; 36(11-12):873-86. PubMed ID: 11755230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
    J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
    Hinschberger A; Butt S; Lelong V; Boulouard M; Dumuis A; Dauphin F; Bureau R; Pfeiffer B; Renard P; Rault S
    J Med Chem; 2003 Jan; 46(1):138-47. PubMed ID: 12502367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of 5-HT3- and 5-HT4-serotonin receptors inhibits colonic functions in conscious rats and mice.
    Nagakura Y; Kontoh A; Tokita K; Tomoi M; Shimomura K; Kadowaki M
    J Pharmacol Exp Ther; 1997 Apr; 281(1):284-90. PubMed ID: 9103508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
    Sato Y; Yamada M; Yoshida S; Soneda T; Ishikawa M; Nizato T; Suzuki K; Konno F
    J Med Chem; 1998 Jul; 41(16):3015-21. PubMed ID: 9685241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution mode of the amide fragment in some new N-[omega-[4-(2-methoxyphenyl)piperazin-1-yl]alkyl]pyrid-2(1H)-ones and their 5-HT1A/5-HT2A activity.
    Paluchowska MH; Bugno R; Charakchieva-Minol S; Bojarski AJ; Wesołowska A
    Pol J Pharmacol; 2001; 53(4):369-76. PubMed ID: 11990083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzimidazole derivatives. Part 1: Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists.
    López-Rodríguez ML; Benhamú B; Viso A; Morcillo MJ; Murcia M; Orensanz L; Alfaro MJ; Martín MI
    Bioorg Med Chem; 1999 Nov; 7(11):2271-81. PubMed ID: 10632037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.